z-logo
Premium
Genetic polymorphisms in UDP‐glucuronosyltransferase 1A6 and 1A7 and the risk for benign Warthin's tumors of the parotid gland
Author(s) -
Lacko Martin,
Voogd Adri C.,
van de Goor Rens C.E.,
Roelofs Hennie M.J.,
te Morsche Rene H.M.,
Bouvy Nicole D.,
Peters Wilbert H.M.,
Manni Johannes J.
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24077
Subject(s) - parotid gland , pleomorphic adenoma , genotype , carcinogen , enzyme , adenolymphoma , salivary gland , biotransformation , detoxification (alternative medicine) , pathology , biology , medicine , cancer research , gene , genetics , biochemistry , alternative medicine
Background Warthin's tumors of the parotid gland are associated with smoking, whereas pleomorphic adenomas are not. Genetic polymorphisms in biotransformation enzymes, involved in detoxification of toxins and carcinogens in cigarette smoke, might modify the corresponding enzyme activity and influence detoxifying capacity. We hypothesize that these genetic polymorphisms may influence the individual risk for Warthin's tumor, but not for pleomorphic adenomas. Methods Blood from 146 patients with benign parotid gland tumors and 437 controls were investigated for polymorphisms in several biotransformation enzymes. Based on these polymorphisms, patients and controls were divided according to predicted enzyme activity (low, intermediate, and high). Results Prevalence of predicted intermediate and high activity UGT1A7 and UGT1A6 genotypes was significantly higher in the patients with Warthin's tumors, but not in patients with pleomorphic adenomas, compared with healthy controls. Conclusion Predicted intermediate and high activity UGT1A7 and UGT1A6 genotypes are associated with an increased risk for Warthin's tumor. © 2015 Wiley Periodicals, Inc. Head Neck 38 : E717–E723, 2016

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here